The U.S. Supreme Court on Monday, May 4, 2026, issued an emergency order restoring broad access to the abortion pill mifepristone, blocking a Fifth Circuit Court of Appeals ruling that had threatened to upend one of the primary methods of abortion provision across the nation.

Background of the Ruling

The appeals court had reinstated a requirement last week that women obtain the pill through in-person doctor visits, reversing years of FDA regulations that allowed mifepristone to be dispensed at pharmacies and sent through the mail. The Supreme Court’s order restores those rules while the legal challenge proceeds.

Most abortions in the United States are obtained with medication — typically a combination of mifepristone and a second drug, misoprostol. The widespread availability of these medications has made abortion accessible to women even in states with abortion bans, through telehealth services and interstate mail delivery.

The emergency order came after Danco Laboratories, the manufacturer of mifepristone, filed an urgent request with the Supreme Court on May 3. Louisiana had sued, arguing that the availability of mifepristone undermined the state’s abortion ban.

Significance of the Decision

The Court’s order allows women seeking abortions to continue obtaining the pill at pharmacies or through the mail, without requiring an in-person visit to a doctor — rules that had been in effect for several years prior to the appeals court ruling.

The decision carries significant political and legal implications. With the 2026 midterm elections approaching, abortion rights remain one of the most contentious issues in American politics. The Supreme Court’s decision preserves the status quo temporarily but does not represent a final ruling on the case.

Reactions

Abortion rights advocates welcomed the Court’s decision, calling it an important step in protecting women’s healthcare access. Opponents criticized the ruling, arguing it disregards states’ authority to regulate medical practice within their borders.

Louisiana’s lawsuit represents a broader effort by several conservative states to restrict access to mifepristone. These states argue that the Food and Drug Administration’s (FDA) relaxed regulatory approach to mifepristone exceeds its statutory authority.

What Comes Next

The Supreme Court’s temporary order means the case will continue to proceed through the appeals process, potentially requiring a final ruling from the Court itself. In the meantime, current access channels for mifepristone remain intact.

Medication abortions account for the majority of all abortions in the United States. The drug’s accessibility has created a stark contrast between states where abortion is legal and those where it is banned, with many women from restrictive states relying on telehealth services and mail delivery to obtain the medication.

Sources: AP News | NBC News | PBS

On Saturday, Danco Laboratories, the pharmaceutical company that makes the abortion pill mifepristone, filed an emergency request with the US Supreme Court to pause a Fifth Circuit Court of Appeals ruling and temporarily restore mail-order access to the drug.

Fifth Circuit Reinstates In-Person Requirement

The Fifth Circuit Court of Appeals, based in Louisiana, temporarily reinstated a requirement on Friday that abortion pills must be obtained in person. The decision will, for now, curb access to abortion pills — the most common method of terminating pregnancies in the US — in states where abortion is banned.

The appeals court wrote in its order: “Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ’every unborn child is human being from the moment of conception and is, therefore, a legal person.'”

Pharmaceutical Company Warns of “Chaos”

Lawyers for Danco warned in their Supreme Court filing: “The resulting chaos for patients, providers, pharmacies, and the drug-regulatory system is a quintessential irreparable harm that underscores the need for emergency relief from this Court.”

Mifepristone is the first drug in a two-pill regimen recommended by the FDA to end a pregnancy. It is widely available in states where abortion is legal.

A History of Regulatory Shifts

In April 2021, the FDA lifted the in-person dispensing requirement for mifepristone during the COVID-19 pandemic, allowing doctors to send pills by mail through telemedicine. In 2023, the FDA permanently lifted that requirement.

However, in 2024 the US Supreme Court unanimously rejected an effort to restrict access to mifepristone — though that ruling left the door open to other attempts to limit the drug’s availability, coming two years after the Court rescinded the nationwide guarantee to abortion rights.

Friday’s appellate order overrides a lower court’s ruling from earlier this month that had paused the case while the Trump administration conducts an FDA review.

Political Divide Continues

Louisiana Attorney General Liz Murrill celebrated the court’s decision, saying the Biden-era rule “facilitated the deaths of thousands of Louisiana babies (and millions in other states).”

“I look forward to continuing to defend women and babies as this case continues,” she added.

Source: BBC News - US Supreme Court asked to restore abortion pill access